XFOR | X4 Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.3522 - 0.3880
52 Week Range	0.2610 - 1.6000
Beta	0.86
Implied Volatility	214.76%
IV Rank	47.26%
Day's Volume	553,955
Average Volume	2,429,312
Shares Outstanding	170,546,000
Market Cap	62,402,781
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-11-16

Valuation
Profitability
Growth
Health
P/E Ratio	-4.57
Forward P/E Ratio	N/A
EPS	-0.08
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	127
Country	USA
Website	XFOR

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

XFOR's peers: ABEO, ABOS, ABSI, ACHV, ADMA, AFMD, AGEN, AKBA, ALDX, ALT, ALZN, AMLX, ANNX, APLS, APLT, ARQT, ATRA, AUTL, BBIO, BCLI, BCRX, BCTX, BHVN, BIVI, BLRX, BPMC, BTAI, CMRX, CNTX, CPRX, CRBP, CRIS, CRVS, CTXR, CUE, CYCN, CYTK, DAWN, DMAC, DTIL, ELDN, ETNB, EXEL, EYPT, GERN, GLSI, GNPX, GOSS, HOOK, HRTX, IBRX, IDYA, INKT, INVA, INZY, KPTI, LPTX, LQDA, LXRX, MDGL, MESO, MIRM, MIST, MREO, MRNS, MRSN, NERV, OCUL, ONCY, ORMP, OTLK, PDSB, PHAT, PIRS, PLX, PRTG, PTGX, PYXS, QURE, RARE, RCUS, RIGL, RXRX, SANA, SLNO, SPRB, TCRX, TERN, TGTX, TSHA, VCEL, VIRX, VKTX, VRNA, VYGR, WVE, XBIT, XERS, EFTR, ELEV, HEPA, ERNA, GPCR

*Chart delayed

Analyzing fundamentals for XFOR we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is wealthy, Growth is desperately bad and Health is very weak. For more detailed analysis please see XFOR Fundamentals page.

Watching at XFOR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on XFOR Technicals page.